What it sells
Gilgamesh Pharmaceuticals, a Clinical stage biotechnology company…
Business model breakdown
Economics: what it saves and how it charges
Pre-revenue drug developer funded by venture rounds ($60M Series A, $39M Series B), AbbVie collaboration/option-to-license deal and a NIDA grant; value via licensing or acquisition.
Distribution: how it reaches customers
UnverifiedPartnering/out-licensing to large pharma and clinical trials rather than direct sales.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2020 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.